Combining radiation and immunotherapy to help patients keep their bladders

Plain-English translation of NCT07061964 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether combining radiation therapy with , an immunotherapy medication, can help people with muscle-invasive bladder cancer keep their bladder instead of having it surgically removed. You would only be eligible if your cancer has already significantly shrunk after your initial chemotherapy treatment. The goal is to see if this combination approach can prevent cancer from returning while preserving bladder function and quality of life.

Currently, the standard treatment for advanced bladder cancer often involves removing the entire bladder, which significantly impacts quality of life. This trial is testing whether this medication combined with radiation can be effective enough to let patients avoid this major surgery while still controlling their cancer.

Do you qualify?

You likely qualify if…

you have muscle-invasive bladder cancer that was diagnosed within the past 6 months
your cancer has already significantly shrunk (to stage T0 or T1) after receiving 3–6 cycles of chemotherapy treatment
imaging tests after chemotherapy show no spread to lymph nodes or distant organs
you had a procedure called TURBT (transurethral resection of bladder tumor) with biopsies within 60 days after your chemotherapy ended
your cancer is confined to the bladder — no cancer found elsewhere in your urinary system in the past 2 years

You likely don't qualify if…

you have small cell carcinoma, neuroendocrine carcinoma, or certain other rare bladder cancer variants
your cancer has spread to lymph nodes or distant organs after chemotherapy
you have cancer in other parts of your urinary system (kidney, ureter) unless you had complete surgical removal
you received fewer than 3 or more than 6 cycles of chemotherapy before this trial
you have had other cancers outside the bladder in the past 2 years, except for certain early-stage upper urinary tract cancers that were completely removed

What participation looks like

You would receive 20 daily radiation treatments over 4 weeks (Monday through Friday), combined with 18 cycles of given intravenously every 3 weeks for about 12 months total. You will have multiple imaging scans, cystoscopy exams (looking inside the bladder), tissue biopsies, and blood tests throughout the study to monitor how well the treatment is working and check for side effects. The trial will also ask you to report any symptoms you experience using questionnaires.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Combining radiation and immunotherapy to help patients keep their bladders

What is this trial?

Do you qualify?

What participation looks like

Trial locations(142 sites)